INT70907

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1997
Last Reported 2010
Negated 1
Speculated 3
Reported most in Body
Documents 30
Total Number 33
Disease Relevance 19.68
Pain Relevance 5.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (EDNRA) signal transduction (EDNRA) aging (EDNRA)
plasma membrane (EDNRA) signal transducer activity (EDNRA)
Anatomy Link Frequency
blood 2
vessels 2
skin 2
sensory neurons 1
limb 1
EDNRA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 395 100.00 Very High Very High Very High
cva 34 100.00 Very High Very High Very High
Kinase C 13 100.00 Very High Very High Very High
anesthesia 7 100.00 Very High Very High Very High
agonist 6 99.92 Very High Very High Very High
local anesthetic 10 99.44 Very High Very High Very High
ischemia 51 96.88 Very High Very High Very High
Neurotransmitter 4 94.84 High High
Calcium channel 20 92.56 High High
Ultiva 4 89.96 High High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 289 99.80 Very High Very High Very High
Increased Venous Pressure Under Development 406 99.64 Very High Very High Very High
Cancer 155 99.52 Very High Very High Very High
Papillomavirus Infection 24 99.32 Very High Very High Very High
Pulmonary Hypertension 782 98.76 Very High Very High Very High
Apoptosis 47 98.76 Very High Very High Very High
Hemorrhage 22 98.72 Very High Very High Very High
Heart Rate Under Development 26 98.60 Very High Very High Very High
Ulcers 10 97.92 Very High Very High Very High
Nociception 11 97.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ET-1 caused contraction was mildly inhibited by BQ-123, an ETA receptor antagonist, and not by BQ-788, an ETB receptor antagonist.
Negative_regulation (inhibited) of ET associated with antagonist
1) Confidence 0.36 Published 2004 Journal Regul. Pept. Section Abstract Doc Link 14749038 Disease Relevance 0 Pain Relevance 0.28
In animal models of PAH, however, positive dilatory effects have been observed with both selective ETA-receptor blockade and non-selective antagonism36 (see Supplementary material online).
Negative_regulation (blockade) of ETA-receptor associated with pulmonary hypertension
2) Confidence 0.35 Published 2008 Journal European Heart Journal Section Body Doc Link PMC2515885 Disease Relevance 0.85 Pain Relevance 0.15
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?


Negative_regulation (Inhibition) of endothelin associated with pulmonary hypertension
3) Confidence 0.35 Published 2008 Journal European Heart Journal Section Title Doc Link PMC2515885 Disease Relevance 0.45 Pain Relevance 0.04
Sitaxentan sodium, a highly selective ETA-receptor antagonist of the sulphonamide class of ETRA, has received approval for the treatment of PAH patients with WHO functional class III symptoms at an oral dose of 100 mg once daily (European Union, Canada, and Australia).
Negative_regulation (antagonist) of ETA-receptor associated with pulmonary hypertension and antagonist
4) Confidence 0.35 Published 2008 Journal European Heart Journal Section Body Doc Link PMC2515885 Disease Relevance 0.47 Pain Relevance 0.08
For example, sitaxentan (in vitro ETA:ETB selectivity >6500:1) acutely decreases ET-1 levels in patients with chronic heart failure,34 indicating that ETB receptors, which play a role in ET-1 clearance, remain functional.
Negative_regulation (decreases) of ET in heart associated with heart rate under development
5) Confidence 0.35 Published 2008 Journal European Heart Journal Section Body Doc Link PMC2515885 Disease Relevance 0.31 Pain Relevance 0.08
BACKGROUND: Several beneficial effects of local anesthetics (LAs) were shown to be due to inhibition of G protein-coupled receptor signaling.
Negative_regulation (inhibition) of protein-coupled receptor associated with local anesthetic
6) Confidence 0.33 Published 2004 Journal Anesthesiology Section Abstract Doc Link 15087620 Disease Relevance 0 Pain Relevance 0.45
Time-dependent inhibition of G protein-coupled receptor signaling by local anesthetics.
Negative_regulation (inhibition) of protein-coupled receptor associated with local anesthetic
7) Confidence 0.33 Published 2004 Journal Anesthesiology Section Title Doc Link 15087620 Disease Relevance 0 Pain Relevance 0.47
When comparing these post hoc analyses, an advantage of selective ETA blockade appears possible, since some of the efficacy endpoints reached statistical significance only with sitaxentan treatment.
Negative_regulation (blockade) of ETA
8) Confidence 0.30 Published 2008 Journal European Heart Journal Section Body Doc Link PMC2515885 Disease Relevance 0.66 Pain Relevance 0
It is a useful finding that in case of elevated transaminases, a switch to another ETRA may be an option.
Negative_regulation (switch) of ETRA
9) Confidence 0.30 Published 2008 Journal European Heart Journal Section Body Doc Link PMC2515885 Disease Relevance 0.28 Pain Relevance 0.08
We therefore hypothesized that ET receptor inhibition with bosentan may improve the efficacy of dacarbazine as therapy for metastatic melanoma, when the two agents are given in combination.
Negative_regulation (inhibition) of ET receptor associated with skin cancer
10) Confidence 0.28 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2856553 Disease Relevance 1.18 Pain Relevance 0.03
Binding studies show that HPV-infected cells express increased numbers of functional ETAR, and a specific antagonist of ETA inhibits ET-1-induced proliferation.
Negative_regulation (numbers) of ETAR associated with papillomavirus infection and antagonist
11) Confidence 0.28 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 2.11 Pain Relevance 0.13
ETAR blockade sensitized tumor cells to the apoptotic potential of chemoterapeutic agent resulting in tumor regression.
Negative_regulation (blockade) of ETAR associated with cancer and apoptosis
12) Confidence 0.28 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 1.08 Pain Relevance 0.20
Desensitization to sarafotoxin S6c, an ET(B) receptor agonist, failed to abolish the response to ET-1, which was completely inhibited by FR-139317.
Negative_regulation (inhibited) of ET associated with agonist
13) Confidence 0.22 Published 2002 Journal Regul. Pept. Section Abstract Doc Link 11959373 Disease Relevance 0 Pain Relevance 0.26
The question of whether differential blockade of ETA offers any advantages in the treatment of PAH would be best answered by randomized clinical trials comparing ETA selective and non-selective agents.
Negative_regulation (blockade) of ETA associated with pulmonary hypertension
14) Confidence 0.21 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.15 Pain Relevance 0.23
Recently, we have shown that ETA receptor blockade by BQ123 markedly increases the nutritive skin microcirculation in patients with type 2 diabetes and microangiopathy (Settergren et al 2008).
Negative_regulation (blockade) of ETA in skin associated with diabetes mellitus
15) Confidence 0.20 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 0.87 Pain Relevance 0.04
The skin nutritive microcirculation determined by nailfold capillary microscopy and the hyperemic response, ie, the peak value of the CBV following arterial occlusion, increased significantly during ETA receptor blockade, indicating improved microvascular reactivity (Figure 2a–b) (Settergren et al 2008).
Negative_regulation (blockade) of ETA in skin
16) Confidence 0.20 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 0.81 Pain Relevance 0.06
Increased TBP during ETA receptor blockade may be due to vasodilation of precapillary resistance vessels.
Negative_regulation (blockade) of ETA in vessels associated with increased venous pressure under development
17) Confidence 0.20 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 0.96 Pain Relevance 0.07
This supports the notion that the ET-1 system is upregulated in patients with type 2 diabetes and that ETA receptor blockade exerts hemodynamic effects only under such conditions.
Negative_regulation (blockade) of ETA associated with diabetes mellitus
18) Confidence 0.20 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 0.92 Pain Relevance 0.05
We conducted a pilot study to investigate whether ETA receptor blockade improves peripheral tissue perfusion in diabetic patients with critical limb ischemia.
Spec (whether) Negative_regulation (blockade) of ETA in limb associated with diabetes mellitus and ischemia
19) Confidence 0.20 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 0.98 Pain Relevance 0.05
G protein-coupled receptor inhibition of these channels is typically voltage-dependent and mediated by Gbetagamma, whereas N-type channels in sensory neurons are sensitive to a second G protein-coupled receptor pathway that inhibits the channel independent of voltage.
Negative_regulation (inhibition) of protein-coupled receptor in sensory neurons
20) Confidence 0.19 Published 2007 Journal Nat. Neurosci. Section Abstract Doc Link 17293861 Disease Relevance 0.10 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox